"A Step-by-Step Guide to Drug Product Registration with EFDA (Ethiopian Food and Drug Authority)"In Ethiopia

"Local Authorized Representative Requirement in Africa:

Why You Can't Register Without One"

Understanding Africa's CTD Dossier Requirements: What Manufacturers Often Get Wrong

Common Queries from EU Authorities (EMA / CHMP) on Module 2.4 & 2.5 for Generic Applications

Best Practices When Preparing 2.4 / 2.5 for Generics

• Maintain scientific tone, avoid copying SmPC text verbatim.

• Include rationale, not just description — show you understand why data are sufficient.

• Use summary tables (literature studies, PK results, safety signals) — assessors prefer concise visuals.

• Clearly reference the BE study report in 5.3, summarizing outcomes in Module 2.5.

• Ensure alignment across modules (e.g. 2.5 ↔ 5.3.1; 2.4 ↔ 5.3.5).

• Include statement of compliance with EMA BE and non-clinical guidance documents.

We take complete ownership of the process for Ethiopia including:

• Triggering GMP inspection and securing approval

• Identifying and appointing a reliable in-market distributor

• Strategic product portfolio finalization

• Commercial agreement structuring with the distributor

• Dossier submission, and sample coordination

• Continuous regulatory follow-up until approvals

• Ensuring smooth commercial operations, including payment flow management.

• Local Agent support